Malta - English - Medicines Authority

eli lilly & co. limited - atomoxetine - hard capsule - atomoxetine 80 mg - psychoanaleptics

Malta - English - Medicines Authority

eli lilly & co. limited - atomoxetine - hard capsule - atomoxetine 100 mg - psychoanaleptics

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - atomoxetine hydrochloride - capsules hard - 10 milligram - centrally acting sympathomimetics

Malta - English - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - atomoxetine - hard capsule - atomoxetine 18 mg - psychoanaleptics

Malta - English - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - atomoxetine - hard capsule - atomoxetine 25 mg - psychoanaleptics

Malta - English - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - atomoxetine - hard capsule - atomoxetine 40 mg - psychoanaleptics

Malta - English - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - atomoxetine - hard capsule - atomoxetine 60 mg - psychoanaleptics

Malta - English - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - atomoxetine - hard capsule - atomoxetine 80 mg - psychoanaleptics

Malta - English - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - atomoxetine - hard capsule - atomoxetine 100 mg - psychoanaleptics

United States - English - NLM (National Library of Medicine)

stat rx usa llc - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine hydrochloride 10 mg - strattera is indicated for the treatment of attention–deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)]. a diagnosis of adhd (dsm–iv) implies the presence of hyperactive–impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic test. adequate diagnosis re